Annexin Pharmaceuticals Investor Relations Material

Annexin Pharmaceuticals AB is a Swedish biotechnology company focused on developing innovative therapies for cardiovascular and inflammatory diseases. Its lead product, ANXV, is a recombinant human protein, Annexin A5, which has the potential to treat conditions related to blood vessel damage and inflammation. The drug is currently undergoing clinical trials, particularly for Retinal Vein Occlusion (RVO), a condition that can lead to vision loss, and shows potential for broader applications, including in oncology. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Stockholm Stock Exchange.